Table 4.

Mean values (±SE) of the clinical (i.e., Geriatric Depression Scale, Clinical Dementia Rating, and Hachinski Ischemic Score) genetic (i.e., Apolipoprotein E genotyping, APOE), and cerebrospinal fluid (i.e., beta amyloid 1-42, Aβ 42; protein tau, t-tau; and phosphorylated form of protein tau, p-tau) data as the results of their statistical comparisons (p < 0.05 corrected) in the groups of noADMCI-noEEA (N = 19) and noADMCI-EEA (N = 13) patients.

	noADMCI-noEEA	noADMCI-EEA	Statistical analyses
Clinical, genetic (APOE) and cerebrospinal fluid markers in noADMCI-noEEA and noADMCI-EEA
CLINICAL MARKERS
Geriatric depression scale (GDS)	2.3 ± 0.5	2.3 ± 0.6	T-test: p = 0.9
Clinical dementia rating (CDR)	0.5 ± 0.0	0.5 ± 0.0	T-test: p = 1.0
Hachinski ischemic score (HIS)	1.2 ± 0.3	1.2 ± 0.2	T-test: p = 0.9
GENETIC MARKER
APOE4 (%)	10.5%	7.7%	Fisher test: p = 0.9
CEREBROSPINAL FLUID MARKERS (pg/mL)
Aβ42	1,000 ± 44	1,087 ± 73	T-test: p = 0.25
p-tau	43 ± 2	51 ± 5	T-test: p = 0.15
t-tau	276 ± 29	343 ± 48	T-test: p = 0.25
Aβ42/p-tau	24 ± 1	23 ± 2	T-test: p = 0.6

All ADMCI patients had all values of those markers available. In line with the inclusion criteria, all noADMCI patients had CDR score of 0.5, GDS score ≤ 5, HIS score ≤ 4, and Aβ 42 level in the cerebrospinal fluid (CSF) > 550 pg/mL.

noADMCI-noEEA, patients with mild cognitive impairment not due to Alzheimer's disease and without epileptiform EEG activity; noADMCI-EEA, patients with mild cognitive impairment not due to Alzheimer's disease and epileptiform EEG activity. No significant difference was observed between the two noADMCI groups even when a marginal threshold of p < 0.05 uncorrected was used.